SCHEMBL13243151

SCHEMBL13243151

CCCCOc1c(F)cc(/C=C(\F)C(=O)OCC)cc1F

nearest known ligand 0.40

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MEN1 O00255 4/20 0.40
KMT2A Q03164 4/20 0.40
MAPT P10636 3/20 0.40
LMNA P02545 2/20 0.40
NPSR1 Q6W5P4 2/20 0.40
CYP1A2 P05177 1/20 0.40
CYP2C9 P11712 1/20 0.40
CYP2C19 P33261 1/20 0.40
ESR1 P03372 2/20 0.37
BACE1 P56817 1/20 0.36
THRA P10827 2/20 0.35
THRB P10828 2/20 0.35
TUBB1 Q9H4B7 2/20 0.35
CCNT1 O60563 1/20 0.35
CCNB2 O95067 1/20 0.35
CCNE2 O96020 1/20 0.35
CDK1 P06493 1/20 0.35
CDK4 P11802 1/20 0.35
CCNB1 P14635 1/20 0.35
CCNA2 P20248 1/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL12056203 0.87 TUBB1 (0.43) MEN1KMT2AMAPTLMNANPSR1
SCHEMBL12056262 0.87 TUBB1 (0.40) MEN1KMT2AMAPTLMNANPSR1
SCHEMBL8374882 0.82 MAPT (0.46) MEN1KMT2AMAPTLMNANPSR1
SCHEMBL8374884 0.82 MAPT (0.46) MEN1KMT2AMAPTLMNANPSR1
SCHEMBL13221558 0.80 NR1H4 (0.52) MEN1KMT2AMAPTLMNANPSR1
SCHEMBL13062424 0.75 THRA (0.48) ESR1THRATHRBMAPK1ALDH1A1
SCHEMBL5438332 0.74 MAPT (0.49) MEN1KMT2AMAPTLMNANPSR1
SCHEMBL5438330 0.74 MAPT (0.49) MEN1KMT2AMAPTLMNANPSR1
SCHEMBL12056204 0.74 GRIN2D (0.41) MEN1KMT2AMAPTLMNANPSR1
SCHEMBL9580520 0.72 MEN1 (0.42) MEN1KMT2AMAPTLMNANPSR1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2690095-A1 Aryl gpr120 receptor agonists and uses thereof Camabay Therapeutics, Inc. (US) 2014-01-29 EP disclosed
US-20100216827-A1 ARYL GPR120 RECEPTOR AGONISTS AND USES THEREOF METABOLEX, INC. 2010-08-26 US disclosed
WO-2010048207-A2 ARYL GPR120 RECEPTOR AGONISTS AND USES THEREOF METABOLEX, INC. (US) 2010-04-29 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100216827-A1 ARYL GPR120 RECEPTOR AGONISTS AND USES THEREOF GPR119, GPR52, GCGR MEN1 4641/4885KMT2A 2399/4885MAPT 4471/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.